Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

The link between estrogen and the development and proliferation of breast cancer is well documented. Estrogen stimulates growth and inhibits apoptosis through estrogen receptor-mediated mechanisms in many cell types. Interestingly, there is strong evidence that estrogen induces apoptosis in breast cancer and other cell types. Forty years ago, before the development of tamoxifen, high-dose estrogen was used to induce tumor regression of hormone-dependent breast cancer in post-menopausal women. While the mechanisms by which estrogen induces apoptosis were not completely known, recent evidence from our laboratory and others demonstrates the involvement of the extrinsic (Fas/FasL) and the intrinsic (mitochondria) pathways in this process. We discuss the different apoptotic signaling pathways involved in E2 (17β-estradiol)-induced apoptosis, including the intrinsic and extrinsic apoptosis pathways, the NF-κB (nuclear factor-kappa-B)-mediated survival pathway as well as the PI3K (phosphoinositide 3-kinase)/Akt signaling pathway. Breast cancer cells can also be sensitized to estrogen-induced apoptosis through suppression of glutathione by BSO (L-buthionine sulfoximine). This finding has implications for the control of breast cancer with low-dose estrogen and other targeted therapeutic drugs.

[1]  V. Jordan,et al.  Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  V. Jordan,et al.  Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis , 2008, Breast Cancer Research.

[3]  G. Mor,et al.  Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER+ breast cancer cells , 2005, Apoptosis.

[4]  R. Pietras,et al.  Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers , 2007, Clinical Cancer Research.

[5]  L. Peso,et al.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.

[6]  Sundeep Khosla,et al.  Sex steroids and the construction and conservation of the adult skeleton. , 2002, Endocrine reviews.

[7]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[8]  R. Bociek,et al.  Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  John Calvin Reed,et al.  Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. , 2003, Cancer research.

[10]  D. Bentrem,et al.  Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  L. Hartmann,et al.  Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis , 1999, Breast Cancer Research and Treatment.

[12]  V. Jordan,et al.  The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. , 2005, Breast.

[13]  R. Santen,et al.  Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. , 2008, Advances in experimental medicine and biology.

[14]  Hong Liu,et al.  Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. , 2003, Journal of the National Cancer Institute.

[15]  Ji-ping Wang,et al.  Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[17]  J. S. Foster,et al.  Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. , 1996, Molecular endocrinology.

[18]  V. Jordan,et al.  Targeting oestrogen to kill the cancer but not the patient , 2004, British Journal of Cancer.

[19]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[20]  C. Reynolds,et al.  Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.

[21]  J. Testa,et al.  A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.

[22]  E. Levin,et al.  Nature of functional estrogen receptors at the plasma membrane. , 2006, Molecular endocrinology.

[23]  V. Jordan,et al.  Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. , 1992, Journal of the National Cancer Institute.

[24]  H. Bailey.  L-S,R-buthionine sulfoximine: historical development and clinical issues. , 1998, Chemico-biological interactions.

[25]  S. Safe,et al.  Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. , 1994, The Journal of biological chemistry.

[26]  G. Mor,et al.  Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. , 2000, Journal of neurobiology.

[27]  L. Ellerby,et al.  Shift of the Cellular Oxidation‐Reduction Potential in Neural Cells Expressing Bcl‐2 , 1996, Journal of neurochemistry.

[28]  R. McPherson,et al.  Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17β-Estradiol , 2001 .

[29]  C. Gélinas,et al.  Current insights into the regulation of programmed cell death by NF-kappaB. , 2006, Oncogene.

[30]  M. Peter,et al.  The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.

[31]  Frederick Naftolin,et al.  Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  Yasmin Sitabkhan,et al.  Estradiol-Induced Regression in T47D:A18/PKCα Tumors Requires the Estrogen Receptor and Interaction with the Extracellular Matrix , 2009, Molecular Cancer Research.

[33]  Tianyu Li,et al.  Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. , 2005, Journal of the National Cancer Institute.

[34]  P. Chambon,et al.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. , 2007, Cell.

[35]  P. O'dwyer,et al.  Role of Jun and Jun kinase in resistance of cancer cells to therapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[36]  V. Jordan.  The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  K. Kim,et al.  Minireview: estrogen receptor-mediated rapid signaling. , 2006, Endocrinology.

[38]  H. Bush,et al.  Breast Cancer Research , 1978, British Journal of Cancer.

[39]  R. Fine,et al.  Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. , 1996, Journal of the National Cancer Institute.

[40]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[41]  Eva Enmark,et al.  Ligand-, Cell-, and Estrogen Receptor Subtype (α/β)-dependent Activation at GC-rich (Sp1) Promoter Elements* , 2000, The Journal of Biological Chemistry.

[42]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[43]  J. Gustafsson,et al.  Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. , 2000, The Journal of biological chemistry.

[44]  M. Cohen-Solal,et al.  Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[45]  N. Sedransk,et al.  Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. , 1977 .

[46]  J. Nör,et al.  Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. Wellstein,et al.  Estradiol rapidly activates Akt via the ErbB2 signaling pathway. , 2003, Molecular endocrinology.

[48]  V. Jordan,et al.  Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. , 2008, Clinical breast cancer.

[49]  G. Wilding,et al.  Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Scherbakov,et al.  NF-κB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis , 2009, Molecular and Cellular Biochemistry.

[51]  A. Haddow,et al.  Influence of Synthetic Oestrogens on Advanced Malignant Disease , 1944, British medical journal.

[52]  L. Khachigian,et al.  Sp1 Phosphorylation Regulates Apoptosis via Extracellular FasL-Fas Engagement* , 2001, The Journal of Biological Chemistry.

[53]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[54]  C Gélinas,et al.  Current insights into the regulation of programmed cell death by NF-κB , 2006, Oncogene.

[55]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[56]  D. Mahvi,et al.  Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. , 1997, Journal of the National Cancer Institute.

[57]  S. Inceman,et al.  HEPARIN AND EMBOLISM , 1976, The Lancet.

[58]  D. Voehringer.  BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. , 1999, Free radical biology & medicine.

[59]  D. Bentrem,et al.  Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  M. Nagarkatti,et al.  Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus. , 2001, Toxicology.

[61]  S. Mani,et al.  Antisense strategies for oncogene inactivation. , 2005, Seminars in oncology.

[62]  P. Lønning,et al.  High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy , 2001, Breast Cancer Research and Treatment.

[63]  Alexei Degterev,et al.  A decade of caspases , 2003, Oncogene.

[64]  William Rostène,et al.  Hormonal regulation of apoptosis in breast cells and tissues , 2000, Steroids.

[65]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[66]  P. Chambon,et al.  Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts , 2007, Cell.

[67]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[68]  S. Teitelbaum.  Osteoclasts: what do they do and how do they do it? , 2007, The American journal of pathology.

[69]  A. Levine,et al.  Actvation of NF-kappaB by the API2/MALT1 Fusions Inhibits p53 Dependant but Not FAS Induced Apoptosis: A Directional Link between NF-?B and p53 , 2004, Cell cycle.

[70]  J. Reginster,et al.  Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. , 2002, The Journal of clinical endocrinology and metabolism.

[71]  S. Safe,et al.  Estrogen-induced retinoic acid receptor alpha 1 gene expression: role of estrogen receptor-Sp1 complex. , 1998, Molecular endocrinology.

[72]  C. Thompson,et al.  Growth factor signaling in cell survival: implications for cancer treatment. , 2001, The Journal of pharmacology and experimental therapeutics.

[73]  V. Jordan,et al.  Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[74]  H. Forman,et al.  Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. , 1999, Experimental cell research.

[75]  V. Jordan,et al.  Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines , 2000, British Journal of Cancer.

[76]  J. Ingle,et al.  Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. , 1981, The New England journal of medicine.

[77]  Rachel Schiff,et al.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. , 2008, Endocrine reviews.

[78]  H. Iwase.  Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer , 2008, Breast cancer.

[79]  F. Ross,et al.  Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF-κB Ligand (RANKL)-induced JNK Activation* , 2001, The Journal of Biological Chemistry.

[80]  J. Russo,et al.  Role of Hormones in Mammary Cancer Initiation and Progression , 2004, Journal of Mammary Gland Biology and Neoplasia.

[81]  Hong Liu,et al.  Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. , 2003, Journal of the National Cancer Institute.

[82]  S. Safe,et al.  Functional synergy between the transcription factor Sp1 and the estrogen receptor. , 1997, Molecular endocrinology.

[83]  R. Ozols,et al.  Glutathione and drug resistance. , 1996, Cancer investigation.

[84]  Y. Tsujimoto.  Bcl-2 Family of Proteins: Life-or-Death Switch in Mitochondria , 2002, Bioscience reports.

[85]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[86]  L. Altucci,et al.  17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. , 1996, Oncogene.

[87]  D. Jeffe,et al.  A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. , 2009 .

[88]  Y. Oh,et al.  Activation of c-Jun N-terminal Kinase Antagonizes an Anti-apoptotic Action of Bcl-2* , 1997, The Journal of Biological Chemistry.

[89]  Hong Liu,et al.  Apoptotic Action of 17β-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo , 2003 .

[90]  I. Todd,et al.  A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.

[91]  S. Altiok,et al.  JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells , 2007, Breast Cancer Research and Treatment.

[92]  David S Ziegler,et al.  Therapeutic targeting of apoptosis pathways in cancer , 2008, Current opinion in oncology.

[93]  R. McPherson,et al.  Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. , 2001, Journal of the National Cancer Institute.

[94]  D. Wolf,et al.  A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[95]  H. Hsu,et al.  Regulation of estrogenic effects by beclin 1 in breast cancer cells. , 2008, Cancer research.

[96]  S. Gansauge,et al.  Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells , 2000, Cancer.

[97]  S. Safe,et al.  Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. , 1998, Endocrinology.